p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer

Biochemical and Biophysical Research Communications

Volumn 339, Issue 3, 2006, Pages 790-796

  Kawamoto, Ken ^a   Enokida, Hideki ^a   Gotanda, Takenari ^a   Kubo, Hiroyuki ^a   Nishiyama, Kenryu ^a   Kawahara, Motoshi ^a   Nakagawa, Masayuki ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Bladder cancer; Methylation; p14ARF; p16INK4a

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN P53; DNA; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; DNA DETERMINATION; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MALE; NUCLEOTIDE SEQUENCE; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION; STATISTICAL SIGNIFICANCE; TUMOR RECURRENCE; AGED; BLADDER TUMOR; CLINICAL TRIAL; DNA METHYLATION; FEASIBILITY STUDY; GENETIC SCREENING; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PROMOTER REGION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEASIBILITY STUDIES; FEMALE; GENETIC SCREENING; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF; URINARY BLADDER NEOPLASMS;

EID: 28844461573     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.11.072     Document Type: Article

References (37)

1. J.N. Eble, G. Sauter, J.I. Epstein, and I.A.E. Sesterhenn Pathology and genetics of tumours of the urinary system and male genital organs World Health Organization classification of tumours 2004 IARC Press Lyon 93 109
2. N.M. Heney, S. Ahmed, M.J. Flanagan, W. Frable, M.P. Corder, M.D. Hafermann, and I.R. Hawkins Superficial bladder cancer: progression and recurrence J. Urol. 130 1983 1083 1086
3. J.M. Fitzpatrick, A.B. West, M.R. Butler, V. Lane, and J.D. O'Flynn Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection J. Urol. 135 1986 920 922
4. S. Holmang, H. Hedelin, C. Anderstrom, and S.L. Johansson The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years J. Urol. 153 1995 1823 1826
5. D. Sidransky, P. Frost, A. Von Eschenbach, R. Oyasu, A.C. Preisinger, and B. Vogelstein Clonal origin bladder cancer N. Engl. J. Med. 326 1992 737 740
6. T. Habuchi, R. Takahashi, H. Yamada, Y. Kakehi, T. Sugiyama, and O. Yoshida Metachronous multifocal development of urothelial cancers by intraluminal seeding Lancet 342 1993 1087 1088
7. I. Orlow, H. LaRue, I. Osman, L. Lacombe, L. Moore, F. Rabbani, F. Meyer, Y. Fradet, and C. Cordon-Cardo Deletions of the INK4A gene in superficial bladder tumors, association with recurrence Am. J. Pathol. 155 1999 105 113
8. L.L. Chang, W.T. Yeh, S.Y. Yang, W.J. Wu, and C.H. Huang Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer J. Urol. 170 2003 595 600
9. B.J. Schmitz-Drager, M. Kushima, P. Goebell, T.W. Jax, C.D. Gerharz, H. Bultel, W.A. Schulz, T. Ebert, and R. Ackermann p53 and MDM2 in the development and progression of bladder cancer Eur. Urol. 32 1997 487 493
10. H. Shiina, M. Igawa, K. Shigeno, Y. Yamasaki, S. Urakami, T. Yoneda, Y. Wada, S. Honda, and M. Nagasaki Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis Oncology 56 1999 239 247
11. C.C. Yang, K.C. Chu, H.Y. Chen, and W.C. Chen Expression of p16 and cyclin D1 in bladder cancer and correlation in cancer progression Urol. Int. 69 2002 190 194
12. H. Primdahl, H. von der Maase, M. Christensen, H. Wolf, and T.F. Orntoft Allelic deletions of cell growth regulators during progression of bladder cancer Cancer Res. 60 2000 6623 6629
13. G. Dominguez, J. Silva, J.M. Garcia, J.M. Silva, R. Rodriguez, C. Munoz, I. Chacon, R. Sanchez, J. Carballido, A. Colas, P. Espana, and F. Bonilla Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors Mutat. Res. 530 2003 9 17
14. M. Esteller Relevance of DNA methylation in the management of cancer Lancet Oncol. 4 2003 351 358
15. M. Esteller, S. Tortola, M. Toyota, G. Capella, M.A. Peinado, S.B. Baylin, and J.G. Herman Hypermethylation-associated inactivation of p14 (ARF) is independent of p16 (INK4a) methylation and p53 mutational status Cancer Res. 60 2000 129 133
16. M. Shiraishi, A.J. Oates, and T. Sekiya An overview of the analysis of DNA methylation in mammalian genomes Biol. Chem. 383 2002 893 906
17. H. Enokida, H. Shiina, M. Igawa, T. Ogishima, T. Kawakami, W.W. Bassett, J.W. Anast, L.C. Li, S. Urakami, M. Terashima, M. Verma, M. Kawahara, M. Nakagawa, C.J. Kane, P.R. Carroll, and R. Dahiya CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer Cancer Res. 64 2004 5956 5962
18. M.S. Benassi, L. Molendini, G. Gamberi, G. Magagnoli, P. Ragazzini, G.A. Gobbi, L. Sangiorgi, L. Pazzaglia, J. Asp, C. Brantsing, and P. Picci Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma Cancer 92 2001 3062 3067
19. M. Sasaki, M. Kaneuchi, N. Sakuragi, and R. Dahiya Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer Cancer Res. 63 2003 3101 3106
20. D. Nojima, K. Nakajima, L.C. Li, J. Franks, L. Ribeiro-Filho, N. Ishii, and R. Dahiya CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma Mol. Carcinogen. 32 2001 19 27
21. I. Orlow, L. Lacombe, G.J. Hannon, M. Serrano, I. Pellicer, G. Dalbagni, V.E. Reuter, Z.F. Zhang, D. Beach, and C. Cordon-Cardo Deletion of the p16 and p15 genes in human bladder tumors J. Natl. Cancer Inst. 87 1995 1524 1529
22. L.A. Ribeiro-Filho, J. Franks, M. Sasaki, H. Shiina, L.C. Li, D. Nojima, S. Arap, P. Carroll, H. Enokida, M. Nakagawa, S. Yonezawa, and R. Dahiya CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer Mol. Carcinogen. 34 2002 187 198
23. L.H. Sobin, and C. Wittekind TNM classification of malignant tumours International Union Against Cancer (UICC) fifth ed. 1997 Wiley-Liss Publications New York pp. 188-190
24. The Japanese Urological Association, the Japanese Society of Pathology. General Rules for Clinical and Pathological Studies on Bladder Cancer, 2nd ed., Kanehara Publishing Co., Tokyo, 1993, pp. 80.
25. R. Dahiya, C. Lee, J. McCarville, W. Hu, G. Kaur, and G. Deng High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma Int. J. Cancer 72 1997 762 767
26. D. Nojima, L.C. Li, A. Dharia, G. Perinchery, L. Ribeiro-Filho, T.S. Yen, and R. Dahiya CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma Cancer 92 2001 2076 2083
27. J.G. Herman, J.R. Graff, S. Myohanen, B.D. Nelkin, and S.B. Baylin Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proc. Natl. Acad. Sci. USA 93 1996 9821 9826
28. M. Esteller, C. Cordon-Cardo, P.G. Corn, S.J. Meltzer, K.S. Pohar, D.N. Watkins, G. Capella, M.A. Peinado, X. Matias-Guiu, J. Prat, S.B. Baylin, and J.G. Herman p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2 Cancer Res. 61 2001 2816 2821
29. Y. Zhang, Y. Xiong, and W.G. Yarbrough ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways Cell 92 1998 725 734
30. L. Chin, J. Pomerantz, and R.A. DePinho The INK4a/ARF tumor suppressor: one gene-two products-two pathways Trends Biochem. Sci. 23 1998 291 296
31. M. Serrano, G.J. Hannon, and D. Beach A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 Nature 366 1993 704 707
32. T. Kamijo, J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 Proc. Natl. Acad. Sci. USA 95 1998 8292 8297
33. J. Pomerantz, N. Schreiber-Agus, N.J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H.W. Lee, C. Cordon-Cardo, and R.A. DePinho The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 Cell 92 1998 713 723
34. Y. Kawada, M. Nakamura, E. Ishida, K. Shimada, E. Oosterwijk, H. Uemura, Y. Hirao, K.S. Chul, and N. Konishi Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas Jpn. J. Cancer Res. 92 2001 1293 1299
35. E. Dulaimi, R.G. Uzzo, R.E. Greenberg, T. Al-Saleem, and P. Cairns Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel Clin. Cancer Res. 10 2004 1887 1893
36. Y. Tada, M. Wada, K. Taguchi, Y. Mochida, N. Kinugawa, M. Tsuneyoshi, S. Naito, and M. Kuwano The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers Cancer Res. 62 2002 4048 4053
37. J.Y. Rao, G.P. Hemstreet 3rd, R.E. Hurst, R.B. Bonner, P.L. Jones, K.W. Min, and Y. Fradet Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis Proc. Natl. Acad. Sci. USA 90 1993 8287 8291